A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs RRx 001 (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Carcinoma; Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms REPLATINUM
- Sponsors EpicentRx
- 08 Jan 2019 Status changed from not yet recruiting to recruiting.
- 14 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Dec 2018.
- 15 Oct 2018 New trial record